Roth Capital analyst Scott Henry reaffirmed a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased his price target to $55, following the company’s …
Roth Capital analyst Scott Henry reiterated a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) with a price target of $10.00, which represents a potential upside …
In a research report issued this morning, Roth Capital analyst Scott Henry downgraded shares of Igi Laboratories (NYSE:IG) from Buy to Neutral and reduced his price target …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Apricus Biosciences (NASDAQ:APRI) with a price target of $4.00, …
In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on Discovery Laboratories (NASDAQ:DSCO) with a price target …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Discovery Laboratories (NASDAQ:DSCO) with a price target …
In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on Derma Sciences (NASDAQ:DSCI) with a $16.75 price target, which …
In a research note released this morning, Roth Capital analyst Scott Henry downgraded shares of BioDelivery Sciences (NASDAQ:BDSI) from a Buy rating to …
In a research report issued yesterday, Roth Capital analyst Scott Henry assigned a Buy rating on Igi Laboratories (NYSE:IG), and increased his price …
Catalyst Pharmaceutical (NASDAQ:CPRX) announced after the close Monday positive top-line results from the pivotal phase 3 clinical trial of Firdapse to treat Lambert-Eaton …
